References

Beijers A, Mols F, Dercksen W, Driessen C, Vreugdenhil G. Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy. The Journal of Community and Supportive Oncology. 2014; 12:(11)401-406 https://doi.org/10.12788/jcso.0086

Binner M, Ross D, Browner I. Chemotherapy-Induced Peripheral Neuropathy: Assessment of Oncology Nurses' Knowledge and Practice. Oncology Nursing Forum. 2011; 38:(4)448-454 https://doi.org/10.1188/11.onf.448-454

Brown M, Farquhar-Smith P. Pain in cancer survivors; filling in the gaps. British Journal of Anaesthesia. 2017; 119:(4)723-736 https://doi.org/10.1093/bja/aex202

Brown MR, Ramirez JD, Farquhar-Smith P. Pain in cancer survivors. British Journal of Pain. 2014; 8:(4)139-153 https://doi.org/10.1177/2049463714542605

Cavaletti G, Pezzoni G, Pisano C Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. Neuroscience Letters. 2002; 322:(2)103-106 https://doi.org/10.1016/s0304-3940(02)00091-5

Cavaletti G, Jann S, Pace A Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System. 2006; 11:(2)135-141 https://doi.org/10.1111/j.1085-9489.2006.00078.x

Calhoun EA, Welshman EE, Chang C-H Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. International Journal of Gynecological Cancer. 2003; 13:(6)741-748 https://doi.org/10.1111/j.1525-1438.2003.13603.x

Cancer Research. Cancer in the UK 2019. Cancer Research. 2019. https://www.cancerresearchuk.org/sites/default/files/state_of_the_nation_april_2019.pdf (accessed 24.1.2020)

Curcio K. Instruments for Assessing Chemotherapy-Induced Peripheral Neuropathy: A Review of the Literature. Clinical Journal of Oncology Nursing. 2016; 20:(2)144-151 https://doi.org/10.1188/16.cjon.20-01ap

Derry S, Rice ASC, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2013; 13:(1) https://doi.org/10.1002/14651858.cd007393.pub3

Dworkin RH, O'Connor AB, Audette J Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update. Mayo Clinic Proceedings. 2010; 85:(3)S3-S14 https://doi.org/10.4065/mcp.2009.0649

Fallon MT. Neuropathic pain in cancer. British Journal of Anaesthesia. 2013; 111:(1)105-111 https://doi.org/10.1093/bja/aet208

Fallon MT, Storey DJ, Krishan A Cancer treatment-related neuropathic pain: proof of concept study with menthol—a TRPM8 agonist. Supportive Care in Cancer. 2015; 23:(9)2769-2777 https://doi.org/10.1007/s00520-015-2642-8

Flatters SJL, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction. Pain. 2006; 122:(3)245-257 https://doi.org/10.1016/j.pain.2006.01.037

Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: Scientific advances and future directions. Psychological Bulletin. 2007; 133:(4)581-624 https://doi.org/10.1037/0033-2909.133.4.581

Haryani H, Fetzer S, Wu C-L, Hsu Y-Y. Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review. Oncology Nursing Forum. 2017; 44:(3)E111-E123 https://doi.org/10.1188/17.onf.e111-e123

Hou S, Huh B, Kim H Treatment of Chemotherapy induced Peripheral Neuropathy: Systematic Review and Recommendations. Pain Physician. 2018; 21:571-592

Lee D, Kanzawa-Lee G, Knoerl R, Wyatt G, Smith EL. Characterization of Internal Validity Threats to Phase III Clinical Trials for Chemotherapy-Induced Peripheral Neuropathy Management: A Systematic Review. Asia-Pacific Journal of Oncology Nursing. 2019; 6:(4) https://doi.org/10.4103/apjon.apjon_14_19

Latremoliere A, Woolf CJ. Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural Plasticity. The Journal of Pain. 2009; 10:(9)895-926 https://doi.org/10.1016/j.jpain.2009.06.012

Molassiotis A, Cheng HL, Lopez V Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer. 2019; 19:(1) https://doi.org/10.1186/s12885-019-5302-4

National Cancer Registration & Analysis Service and Cancer Research UK. Chemotherapy, Radiotherapy and Tumour Resections in England: 2013-2014. 2017. http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/main_cancer_treatments (accessed 6 March 2020)

NICE. Neuropathic pain in adults: pharmacological management in non-specialist settings. 2013. https://www.nice.org.uk/guidance/cg173 (accessed 10 March 2020)

Oh P-J, Kim YL. Effectiveness of Non-Pharmacologic Interventions in Chemotherapy Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Journal of Korean Academy of Nursing. 2018; 48:(2) https://doi.org/10.4040/jkan.2018.48.2.123

Proudfoot CJ, Garry EM, Cottrell DF Analgesia Mediated by the TRPM8 Cold Receptor in Chronic Neuropathic Pain. Current Biology. 2006; 16:(16)1591-1605 https://doi.org/10.1016/j.cub.2006.07.061

Reyes-Gibby CC, Anderson KO, Todd KH. Risk for Opioid Misuse Among Emergency Department Cancer Patients. Academic Emergency Medicine. 2016; 23:(2)151-158 https://doi.org/10.1111/acem.12861

Smith EML, Campbell G, Tofthagen C Nursing Knowledge, Practice Patterns, and Learning Preferences Regarding Chemotherapy-Induced Peripheral Neuropathy. Oncology Nursing Forum. 2014; 41:(6)669-679 https://doi.org/10.1188/14.onf.669-679

Sun V, Borneman T, Piper B, Koczywas M, Ferrell B. Barriers to pain assessment and management in cancer survivorship. Journal of Cancer Survivorship. 2008; 2:(1)65-71 https://doi.org/10.1007/s11764-008-0047-0

Tanay MA, Armes J. Lived experiences and support needs of women who developed chemotherapy˛induced peripheral neuropathy following treatment for breast and ovarian cancer. European Journal of Cancer Care. 2019; 28:(3) https://doi.org/10.1111/ecc.13011

Tofthagen C, Visovsky CM, Hopgood R. Chemotherapy-Induced Peripheral Neuropathy. Clinical Journal of Oncology Nursing. 2013; 17:(2)138-144 https://doi.org/10.1188/13.cjon.138-144

van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. Journal of Pain and Symptom Management. 2016; 51:(6)1070-1090.e9 https://doi.org/10.1016/j.jpainsymman.2015.12.340

Xiao WH, Bennett GJ. Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-l-carnitine. Pain. 2008; 135:(3)262-270 https://doi.org/10.1016/j.pain.2007.06.001

Zajaczkowska R, Kocot-K˛pska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. International Journal of Molecular Sciences. 2019; 20:(6) https://doi.org/10.3390/ijms20061451

Oncology

Prescribing for persistent cancer pain: focus on chemotherapy-induced peripheral neuropathy

02 April 2020
Better Practice
02 April 2020
Volume 2 · Issue 4

Abstract

Chemotherapy-Induced peripheral neuropathy is rapidly becoming a growing problem faced by healthcare processionals and individuals living with and beyond cancer. The incidence of cancer diagnoses is increasing and, as a result, so is the incidence of individuals living with the consequences of cancer treatment. Chemotherapy-induced peripheral neuropathy is a complex symptom, and its incidence and impact on quality of life varies across treatment modalities. This complexity continues into its assessment and management, and healthcare professionals require more support and guidance when presented with this pain state. This article will explore the current literature surrounding assessment methods and management strategies that will enable prescribers to make informed decision when encountering chemotherapy-induced peripheral neuropathy.

The incidence of a cancer diagnosis within the UK is rising, with an estimated increase of 40% by 2035 (Cancer Research, 2019). However, as treatment modalities and screening become more sophisticated there are more individuals living longer with and as a result of a cancer diagnosis (Cancer Research, 2019).

As the incidence of cancer increases, so does the incidence of individuals living with pain as a direct result of cancer treatment. It is estimated that 66% of individuals with advanced disease and 39% who have completed curative treatment will report pain (Van den Beuken-van Everdingen et al, 2016). Persistent cancer pain is complex and multifactorial, and can have a detrimental impact on patients' quality of life, as it affects not only physical domains but also has a significant impact on psychosocial domains (Sun et al, 2008). Despite the complex nature of persistent cancer pain, it remains poorly understood and managed (Sun et al, 2008).

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month

Register
Or continue by

Signing in with your registered email address

Cancer pain
persistent pain
chronic pain
neuropathic pain
chemotherapy
neuropathy
peripheral neuropathy